In the case of the in vivo studies, our results show that the double injection of 10 mg/kg of LHRH-conjugated prodigiosin or LHRH-conjugated paclitaxel (within a two-week period) eliminates early stage breast tumors (14-days tumor-treatment group). This evidence concerns the gene GNRH1 and neoplasm.